DEA, SAMHSA Buprenorphine and Telemedicine COVID-19 Guidance

dea-samhsa-buprenorphine-telemedicine.pdf

DEA and SAMHSA Buprenorphine and Telemedicine COVID-19 Guidance In light of the coronavirus pandemic, the Drug Enforcement Administration (DEA) has partnered with SAMHSA to ensure authorized practitioners may admit and treat new patients with opioid use disorder (OUD) during the public health emergency.   Read More